Logo
Voyager Therapeutics, Inc.
biotechnology
Phone
(857) 259-5340
Employees
220
Headquarters
75 Sidney Street, Cambridge, Massachusetts, United States, 02139
Headquarters
75 Sidney Street, Cambridge, Massachusetts, United States, 02139
gene therapy, biotechnology, adeno associated virus, research, parkinsons disease, clinical operations, huntingtons disease, vector engineering, sf9, alzheimers disease, als, amyotrophic lateral sclerosis, vysod101, friedrichs ataxia, sod1, tauopathies, and gene therapy, health care, genetics, life science, health, wellness & fitness
About Voyager Therapeutics, Inc.

Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (ad...
Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company's pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson's disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer's disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com. Follow Voyager on LinkedIn. ----- Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics was launched in 2014 with funding from leading life sciences investor Third Rock Ventures and is headquartered in Cambridge, Mass.
Compay BGContact Information
Join Apollo to reach decision makers at Voyager Therapeutics, Inc.
Contacts at Voyager Therapeutics, Inc.

Associate Director
Scientist II, Vector Engineering
Global Reg-CMC Consultant
Senior Director, Quality Assurance
Head, Patient Advocacy & Engagement
Research Associate II
Program Manager
Associate Engineer II
Senior Manager Accounting
Talent Acquisition Lead
Notable Alumni

Scientist - In-Vivo Pharmacology - Cobalt Biomedicine, Inc.

Senior Manager, Regulatory Affairs - Kala Pharmaceuticals

Associate Research Professor - POSTECH 정보통신대학원

IT Specialist - MA Bio Site Ops - Takeda

Associate Director, Formulation & Drug Product Process Development Lead (AAV Gene Therapy) - Homology Medicines, Inc.

Senior Research Associate - Surface Oncology Inc.

Sr. Director, Biologics - Amagma Therapeutics

Clinical Operations Consultant - Curis

VP of Manufacturing - StrideBio, Inc

Browse Apollo's Directories

Company Search

Company Directory Search

People Search

People Directory Search

Find Verified Emails in Seconds

Use Apollo to easily get in touch with anyone in the world